{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.","slug":"developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d","published_at":"2026-03-09T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18788098-developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18788098-developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development ...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CE…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2910,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/developing-novel-cancer-drugs-on-a-budget-with-iterion-therapeutics-rahul-aras-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}